Zorifertinib for lung cancer that has spread to the brain
Part of Cancer clinical trials.
This trial tracks how well zorifertinib works as a first treatment for people with a specific type of advanced lung cancer that has spread to the brain or spinal cord lining. Participants may receive zorifertinib or another standard treatment, and researchers will monitor their response over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have advanced non-small cell lung cancer with an EGFR mutation (L858R or Exon 19 deletion) that cannot be removed with surgery or radiation.
- Your cancer has spread to the brain and/or the lining of the brain and spinal cord.
- You have not received any prior treatment for advanced lung cancer (for the main group taking zorifertinib).
- You are willing to take zorifertinib or another standard treatment as your first therapy for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new targeted pill (zorifertinib) and chemotherapy given directly into the cerebrospinal fluid for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord (leptomeningeal metastasis) and has worsened despite using a third-generation EGFR-TKI drug. The goal is to control the cancer in the nervous system and improve symptoms.
This trial tests a new drug, zorifertinib, combined with osimertinib for people whose lung cancer has spread to the lining of the brain (meninges) and continued to grow despite osimertinib treatment. The goal is to see if this combination can better control the brain spread.
This trial tests a combination of a targeted therapy (firmanertinib), a biologic drug that blocks blood vessel growth (bevacizumab), and a chemotherapy given into the spinal fluid (pemetrexed) for people with non-small cell lung cancer that has spread to the membranes around the brain (leptomeningeal metastasis). The goal is to see if this treatment helps control the cancer and improve symptoms.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
This trial tests a new drug called zongertinib combined with chemotherapy, with or without pembrolizumab (an immunotherapy), for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The goal is to see how safe and well-tolerated the combination is.
This trial tests a new targeted pill (limertinib) combined with radiation therapy for people with a specific type of lung cancer (EGFR-mutant) that has spread to the brain. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new EGFR Mutant Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.